Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Insilico Medicine and Usynova Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drugs with AI


News provided by

Insilico Medicine Hong Kong Limited

05 Aug, 2021, 10:10 GMT

Share this article

Share toX

Share this article

Share toX

SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, and Usynova announced to reach strategic cooperation in advancing the development of novel therapies.

Continue Reading
This image opens in the lightbox
Insilico Medicine and Usynova Announce Strategic Partnership

The agreement outlines a constructive framework where the two parties will combine the advantages of Insilico Medicine's AI-powered drug discovery platform with Usynova's experience in the small molecule innovative drug development to accelerate the development of small molecule innovative drugs, with a view to jointly addressing significant unmet medical needs and tackling novel and challenging targets in cancer and autoimmune diseases.

Insilico Medicine is a global leader in AI-powered drug discovery companies. Since 2014, Insilico Medicine developed the AI-powered drug discovery platform consisting of PandaOmics™ AI-powered novel target discovery engine, Chemistry42™ deep generative reinforcement learning system allowing for the de-novo design of novel molecules with the desired properties that do not exist in the known chemical space, and InClinico™, which predicts clinical trial outcome.

Usynova is an innovative enterprise on drug R&D, the founding team members of which come from multinational pharmaceutical enterprises and domestic CRO leading companies and possess rich experience in drug R&D. Focusing on the two major areas of autoimmune diseases and cancer, the enterprise has built platforms for small molecule chemical drugs and biomacromolecule drugs, developed several pipeline products at different R&D stages, and carried out two clinical trials. The cooperation between the two parties will accelerate the introduction of first-in-class and best-in-class small molecule innovative drugs to patients worldwide.

"China is on the path to becoming the source of truly innovative medicines for the world. We are very pleased to contribute to this important trend by partnering with the innovative biotechnology company, Usynova, to discover novel biomedicines utilizing the latest advances in next-generation artificial intelligence", said Dr. Alex Zhavoronkov, CEO of Insilico Medicine.

"We are honored to be a partner with Usynova, who takes the commitment to develop First-in-Class and Best-in-Class drugs. Insilico Medicine will make full use of the advantages of the AI-powered drug discovery platform, accelerate the R&D of small molecule innovative drugs of Usynova from the aspects of target screening, molecular design, compound synthesis, and work together with Usynova to provide subversive and efficient solutions for unmet clinical needs", said Dr. Ren Feng, the Chief Scientist of Insilico Medicine.

"Insilico Medicine has unique technical capabilities in target discovery and generative chemistry. We hope that the cooperation between the two parties can effectively improve the efficiency and accuracy of small molecule drug R&D. The combination of innovative drug companies and artificial intelligence (AI) technology platforms will definitely change the traditional model of innovative drug R&D in the future. Especially the fact that AI technology provides a new solution for discovering preclinical candidates compounds for novel and difficult targets. We are committed to explore an efficient drug R&D path jointly", said Dr. Hu Tao, the Chief Executive Officer of Usynova.

"Usynova's innovation focuses on the R&D in the fields of cancer and autoimmune diseases and aiming at meeting unmet medical needs. We are pleased to apply Insilico Medicine's cutting-edge AI technology platform to conduct in-depth explorations on novel target identification and drug development for novel and difficult targets. We are aiming to develop first-in-class drugs for the benefit of the cancer and autoimmune patients worldwide", said Dr. Peng Shengbin, the Chief Scientist of Usynova.

About Insilico Medicine

Insilico Medicine, an end-to-end artificial intelligence driven drug discovery company,develops artificial intelligence systems Pharma.AI(www.insilico.com/platform/)that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for identify the novel target and generate new molecular structures with specific properties, and provides breakthrough solution for the discovery and development of innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and aging-related diseases. Since its inception in 2014, Insilico Medicine has reached strategic collaboration with more than 30 drug development companies in the United States, Europe, China, Japan and other countries and regions, and launched new multiple internal R&D pipelines for novel, difficult and previously undruggable targets.

About Usynova

Usynova Pharmaceuticals Ltd. (Shanghai) is an innovative drug R&D enterprise established in January 2020. The enterprise focuses on the treatment of autoimmune diseases and cancer. With the establishment of small molecule drug platforms and biomacromolecule drug platforms, it currently has nearly 10 pipeline products at different R&D stages. Among these product, the indications of UA007 are chemotherapy-induced diarrhea (CID) and chemotherapy-induced neutropenia (CIN). the Phase IIa clinical trial of such product have been completed with excellent POC results, and multiple phase IIb clinical trials are ongoing currently. The product has a number of global patents, and has been funded by the special national project on major new drug R&D. CID is one of the main side effects of cancer chemotherapy, and it is also an important reason for patients to withdraw from chemotherapy. However, there are no effective therapeutic drugs for CID currently. Small molecule pipeline products for targets with poor druggability will also be advanced to the clinical stage in the next few years. The enterprise has established a complete team covering early drug discovery, protein drug production, antibody preparation, pre-clinical and clinical studies, and drug registration application.

Contact: pr@insilico.com

Photo - https://mma.prnewswire.com/media/1589152/Usynova_image.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.